Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis ("ProDERM Study").
Aggarwal, Rohit MD a,*; Charles-Schoeman, Christina MD b; Schessl, Joachim MD c; Dimachkie, Mazen M. MD d; Beckmann, Irene e; Levine, Todd MD f
[Article] Medicine. 100(1):e23677, January 08, 2021.

(Format: HTML, PDF)